Advertisement
BNGO vs DRIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNGO is a Hold and DRIO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BNGO’s FA Score shows that 1 FA rating(s) are green whileDRIO’s FA Score has 1 green FA rating(s).
- BNGO’s FA Score: 1 green, 4 red.
- DRIO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BNGO’s TA Score shows that 3 TA indicator(s) are bullish while DRIO’s TA Score has 4 bullish TA indicator(s).
- BNGO’s TA Score: 3 bullish, 5 bearish.
- DRIO’s TA Score: 4 bullish, 6 bearish.
Price Growth
BNGO (@Pharmaceuticals: Other) experienced а -0.86% price change this week, while DRIO (@Services to the Health Industry) price change was -11.33% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.31%. For the same industry, the average monthly price growth was -0.98%, and the average quarterly price growth was -14.76%.
The average weekly price growth across all stocks in the @Services to the Health Industry industry was -1.92%. For the same industry, the average monthly price growth was -1.20%, and the average quarterly price growth was -13.16%.
Reported Earning Dates
BNGO is expected to report earnings on Jul 30, 2026.
DRIO is expected to report earnings on Aug 17, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.31% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Services to the Health Industry (-1.92% weekly)This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.
| BNGO | DRIO | BNGO / DRIO | |
| Capitalization | 13.2M | 46.4M | 28% |
| EBITDA | -21.63M | -34.02M | 64% |
| Gain YTD | -24.837 | -44.288 | 56% |
| P/E Ratio | 0.00 | N/A | - |
| Revenue | 28.7M | 21.2M | 135% |
| Total Cash | 14.4M | 20M | 72% |
| Total Debt | 17M | 31.8M | 53% |
BNGO | DRIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 51 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 99 | |
PRICE GROWTH RATING 1..100 | 76 | 83 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DRIO's Valuation (24) in the Medical Specialties industry is in the same range as BNGO (25) in the Biotechnology industry. This means that DRIO’s stock grew similarly to BNGO’s over the last 12 months.
DRIO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BNGO (100) in the Biotechnology industry. This means that DRIO’s stock grew similarly to BNGO’s over the last 12 months.
DRIO's SMR Rating (99) in the Medical Specialties industry is in the same range as BNGO (99) in the Biotechnology industry. This means that DRIO’s stock grew similarly to BNGO’s over the last 12 months.
BNGO's Price Growth Rating (76) in the Biotechnology industry is in the same range as DRIO (83) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to DRIO’s over the last 12 months.
BNGO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as DRIO (100) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to DRIO’s over the last 12 months.
| BNGO | DRIO | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Advances ODDS (%) | 6 days ago 74% | 15 days ago 76% |
| Declines ODDS (%) | 19 days ago 89% | 2 days ago 89% |
| BollingerBands ODDS (%) | N/A | 2 days ago 89% |
| Aroon ODDS (%) | 6 days ago 69% | 2 days ago 86% |
Advertisement